Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies

The adoptive transfer of allogeneic CAR NK cells holds great promise as an anticancer modality due to the relative ease of manufacturing and genetic modification of NK cells, which translates into affordable pricing. Compared to the pronounced efficacy of CAR T cell therapy in the treatment of B cel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sergey Kulemzin, Igor Evsyukov, Tatiana Belovezhets, Alexander Taranin, Andrey Gorchakov
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	CAR T cell CAR NK cell cancer immunotherapy Medicine R
Acceso en línea:	https://doaj.org/article/a2b72c875ab4462e8f8d81b911b3bbf0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2b72c875ab4462e8f8d81b911b3bbf0
record_format	dspace
spelling	oai:doaj.org-article:a2b72c875ab4462e8f8d81b911b3bbf02021-11-25T18:07:50ZHorses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies10.3390/jpm111111822075-4426https://doaj.org/article/a2b72c875ab4462e8f8d81b911b3bbf02021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1182https://doaj.org/toc/2075-4426The adoptive transfer of allogeneic CAR NK cells holds great promise as an anticancer modality due to the relative ease of manufacturing and genetic modification of NK cells, which translates into affordable pricing. Compared to the pronounced efficacy of CAR T cell therapy in the treatment of B cell malignancies, rigorous clinical and preclinical assessment of the antitumor properties of CAR NK cells has been lagging behind. In this brief review, we summarize the biological features of NK cells that may help define the therapeutic niche of CAR NK cells as well as create more potent NK cell-based anticancer products. In addition, we compare T cells and NK cells as the carriers of CARs using the data of single-cell transcriptomic analysis.Sergey KulemzinIgor EvsyukovTatiana BelovezhetsAlexander TaraninAndrey GorchakovMDPI AGarticleCAR T cellCAR NK cellcancer immunotherapyMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1182, p 1182 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	CAR T cell CAR NK cell cancer immunotherapy Medicine R
spellingShingle	CAR T cell CAR NK cell cancer immunotherapy Medicine R Sergey Kulemzin Igor Evsyukov Tatiana Belovezhets Alexander Taranin Andrey Gorchakov Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
description	The adoptive transfer of allogeneic CAR NK cells holds great promise as an anticancer modality due to the relative ease of manufacturing and genetic modification of NK cells, which translates into affordable pricing. Compared to the pronounced efficacy of CAR T cell therapy in the treatment of B cell malignancies, rigorous clinical and preclinical assessment of the antitumor properties of CAR NK cells has been lagging behind. In this brief review, we summarize the biological features of NK cells that may help define the therapeutic niche of CAR NK cells as well as create more potent NK cell-based anticancer products. In addition, we compare T cells and NK cells as the carriers of CARs using the data of single-cell transcriptomic analysis.
format	article
author	Sergey Kulemzin Igor Evsyukov Tatiana Belovezhets Alexander Taranin Andrey Gorchakov
author_facet	Sergey Kulemzin Igor Evsyukov Tatiana Belovezhets Alexander Taranin Andrey Gorchakov
author_sort	Sergey Kulemzin
title	Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
title_short	Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
title_full	Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
title_fullStr	Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
title_full_unstemmed	Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
title_sort	horses for courses in the era of cars: advancing car t and car nk cell therapies
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a2b72c875ab4462e8f8d81b911b3bbf0
work_keys_str_mv	AT sergeykulemzin horsesforcoursesintheeraofcarsadvancingcartandcarnkcelltherapies AT igorevsyukov horsesforcoursesintheeraofcarsadvancingcartandcarnkcelltherapies AT tatianabelovezhets horsesforcoursesintheeraofcarsadvancingcartandcarnkcelltherapies AT alexandertaranin horsesforcoursesintheeraofcarsadvancingcartandcarnkcelltherapies AT andreygorchakov horsesforcoursesintheeraofcarsadvancingcartandcarnkcelltherapies
_version_	1718411575347380224

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies

Ejemplares similares